The Hindu Business Line : WHO approves Ranbaxy’s AIDS drug

New Delhi, Aug. 1 Ranbaxy Laboratories Ltd announced on Friday that the World Health Organisation (WHO), Geneva, has approved and included another of the company’s Anti Retrovirals (ARV) drug in its pre-qualification list.

The product, Abacavir 300 mg tablets, will be manufactured at Ranbaxy’s WHO Pre-Qualified manufacturing site at Paonta Sahib.

Abacavir is a nucleoside reverse transcriptase inhibitor and is widely used as part of first line Anti Retroviral treatment around the world.

Commenting on the inclusion, Mr Malvinder Mohan Singh, CEO and Managing Director, Ranbaxy, said, “We are pleased to have one more product on the WHO pre-qualification list. This is yet another significant step in our effort to offer high quality, affordable ARV medicines, for the benefit of the needy HIV patients in the developing and developed parts of the world. We remain committed to supporting the global fight against HIV/AIDS.”

With the inclusion of Abacavir 300 tablets, Ranbaxy now has 18 ARVs on the WHO pre-qualification list, including three USFDA approvals.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Adani in power purchase deal with Maharashtra State Electricity Co

Kesoram opts for ECB of Rs 460 cr

Strides Arcolab completes 50.1% acquisition of Genepharm

Goa Carbon lines up Rs 700-cr investment

Electromech to set up facility at Sriperumbudur

Tata Steel sets up holding co for overseas assets

WHO approves Ranbaxy’s AIDS drug

Bajaj Auto forks out Rs 500 cr to settle Akurdi workers’ dues

GM puts off Hummer, Cadillac launch plans

Texmaco joins Japanese consortium to bid for Madhepura project

Toyota’s small car may be high speed, not low cost